JonesResearch analyst Justin Walsh views the selloff in shares Perspective Therapeutics (CATX) yesterday after the company reported initial results from its ongoing Phase I/IIa trial of Pb-212-VMT-alpha-NET for the treatment of unresectable or metastatic somatostatin receptor type 2 neuroendocrine tumors who have not received prior radiopharmaceutical therapies as a buying opportunity. The significant negative stock reaction was in response to perceptions that the efficacy fell short of the high expectations that were established with the asset’s performance in the investigator initiated trial in India, the analyst tells investors in a research note. However, Jones sees the results as too immature to appropriately evaluate or compare on efficacy and does not view the readout negatively. It keeps a Buy rating on Perspective with a $21 price target
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CATX:
- Perspective Therapeutics Inc trading resumes
- Perspective Therapeutics Inc trading halted, volatility trading pause
- Perspective Therapeutics to pursue dose escalation in Phase 1/2a clinical trial
- Perspective Therapeutics Reports Strong Cash Position and Clinical Advances
- Is CATX a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
